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 ABSTRACT  
 Objectives  To assess the sensitivity of the phagocyte-
specifi c molecules myeloid-related protein (MRP) 8 and 
MRP14 (calprotectin) for monitoring disease activity during 
anti-interleukin (IL)-1 therapies in patients with cryopyrin-
associated periodic syndromes (CAPS), including familial 
cold autoinfl ammatory syndrome (FCAS), Muckle–Wells 
syndrome (MWS) and chronic infantile neurological, 
cutaneous and articular (CINCA) syndrome. 
 Methods  A total of 39 patients with CAPS, including 
5 FCAS, 16 MWS and 18 CINCA syndrome, received 
anti-IL-1 therapy. All patients with CINCA and 12 with 
MWS were treated with IL-1Ra (anakinra), 14 patients 
with MWS with a monoclonal anti-IL-1β antibody 
(canakinumab) and patients with FCAS received IL-1 Trap 
(rilonacept). During serial clinical visits serum amyloid A, 
C-reactive protein, erythrocyte sedimentation rate and 
MRP8/14 serum levels were analysed. 
 Results  Untreated patients with CAPS had signifi cantly 
elevated MRP8/14 values. In response to treatment 
there was a signifi cant reduction of MRP8/14 levels in 
CINCA (2,830 (range 690 – 8,480) ng/ml to 670 ng/
ml, p < 0.001) and MWS patients (anakinra-treated: 
4,390 (1790 – 9780) ng/ml to 1,315 ng/ml (p = 0.003); 
canakinumab-treated: 3,000 (500 – 13060) ng/ml to 
630 ng/ml (p=0.001)). However, in many patients with 
CAPS, MRP8/14 levels were still elevated compared with 
healthy individuals, refl ecting residual disease activity. 
However, canakinumab-treated patients with CAPS 
showed normalised MRP8/14 levels, suggesting control 
of phagocyte activation. 
 Conclusions  Monitoring of cellular systems involved 
in infl ammatory cascades of the innate immunity was 
successfully applied to the IL-1-driven CAPS diseases. 
This is the fi rst study illustrating different states of 
subclinical disease activity in all types of CAPS depending 
on the type of anti-IL-1 therapy. MRP8/14 is a sensitive 
biomarker for monitoring disease activity, status of 
infl ammation and response to IL-1 blockade in patients 
with CAPS. 
 INTRODUCTION 
 Cryopyrin-associated periodic syndromes (CAPS) 
comprise a group of rare autoinfl ammatory diseases, 
which include the familial cold autoinfl ammatory 
syndrome (FCAS), the Muckle–Wells syndrome 
(MWS), and the chronic infantile neurological, 
cutaneous, and articular (CINCA) syndrome. 
 Different mutations in the  NLRP3 (also known as 
 CIAS1/NALP3/PYPAF1) gene locus 1q44, encoding 
for cryopyrin/NALP3 protein, are the cause of CAPS. 
Cryopyrin regulates the production of proinfl am-
matory cytokines, such as interleukin (IL)-1β, by 
controlling the assembly of proteins forming the 
infl ammasome complex. The integrity of the infl am-
masome structure is essential for caspase-1 activity 
which induces the conversion of pro-IL-1β to biologi-
cally active IL-1β. 1 – 4 Uncontrolled pro-IL-1β process-
ing results in a constitutive excess of IL-1β release 
from phagocytic cells of patients with CAPS. 5 – 7 
 Patients with CAPS often show fever, pseudourti-
carial skin rash, joint involvement of varying degree, 
sensorineural hearing loss and eye involvement asso-
ciated with neutrophil-mediated infl ammation and 
an intense acute-phase response. CAPS represents a 
continuum of clinical manifestations in which FCAS 
shows the mildest, CINCA the most severe and 
MWS an intermediate-severity phenotype. 
 Today, targeted treatments are available for 
CAPS. Anti-IL-1 therapy is highly effective in 
CAPS such as MWS. 8 – 11 Anakinra is a recombinant 
non-glycosylated form of the human IL-1 recep-
tor antagonist (IL-1Ra) which blocks the biological 
activity of IL-1β and IL-1α by competitively inhib-
iting the binding of IL-1 to the IL-1 type I receptor 
(IL-1RI). 12 The long-acting IL-1 inhibitor rilonacept 
(IL-1 Trap) is a fusion molecule comprising the 
extracellular component of the IL-1 receptor and 
the Fc portion of IgG1, with high affi nity to IL-1β 
and IL-1α. 13 Recently, another IL-1 inhibiting drug 
was developed. Canakinumab is a human mono-
clonal antibody targeted to IL-1β, which has been 
shown to provide selective and sustained blockade 
of IL-1β. 14  15 While anti-IL-1 therapies improve 
clinical disease activity, it is not entirely clear if the 
complex disease mechanisms leading to infl am-
matory complications of CAPS are completely 
resolved at the molecular level. IL-1 hypersecretion 
is not easy to determine in vivo, and it is obviously 
only one factor among several involved in a com-
plex immune dysregulation, including phagocyte 
activation during autoinfl ammation. 16 
 Infl ammatory markers can help to detect residual 
disease activity and to adjust the treatment to the 
individual needs. Classical and commonly elevated 
infl ammatory markers in patients with CAPS include 
serum amyloid A (SAA) and C-reactive protein (CRP) 
as markers of the acute phase response and infl amma-
tion, and the erythrocyte sedimentation rate (ESR). 9 
 The promising biomarkers MRP8 (myeloid-
related protein 8, also known as S100A8) and 
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MRP14 (S100A9) are phagocyte-specifi c proteins belonging to the 
novel group of damage-associated molecular pattern molecules 
(DAMPs), representing danger signals which share characteristics 
of cytokines. 17  18 DAMP proteins represent endogenous ligands 
of pattern recognition receptors like the receptor for advanced 
glycation end products and the Toll-like receptors. 17 MRP8 and 
MRP14 are secreted by activated phagocytes and bind to Toll-like 
receptor 4 which mediates downstream signalling and promotes 
infl ammation 19 and autoimmunity. 20 
 Patients with juvenile idiopathic arthritis (JIA) show elevated 
MRP8/14 serum levels which correlate with individual disease 
activity, and moreover are predictive for disease fl ares after 
induction of clinical remission. 21 Recently, we dissected the 
positive feedback mechanism of MRP8/MRP14 and IL-1β in 
systemic juvenile idiopathic arthritis and showed that MRP8/
MRP14 serum levels are surrogate markers of IL-1β in patients 
with MWS. 15  16 Although the exact role of the S100-DAMPs in 
autoinfl ammatory syndromes has not yet been fully unravelled, 
these proteins are promising markers of IL-1β-driven infl amma-
tion in CAPS. The aims of this study were to determine serum 
levels of MRP8/14 in patients with CAPS with phenotypes of 
different severity before and during different strategies of IL-1 
blockade in correlation with the clinical effi cacy of treatment. 
 PATIENTS AND METHODS 
 Study design 
 A prospective cohort study of consecutive patients diagnosed 
with active CAPS at the participating centres was performed 
between September 2003 and August 2008. The cohort of patients 
with CINCA and FCAS was included at the National Institute 
of Arthritis and Musculoskeletal and Skin Diseases. 8  13 Patients 
with MWS were included at the University Hospital Tuebingen, 
Department of Pediatrics. 22 The study was approved by the insti-
tutional ethics committee at each centre, and written informed 
consent was obtained from patients or their legal guardians. 
 Patients 
 All patients showed clinical features of active FCAS, CINCA or 
MWS and required medical intervention. Eighteen patients with 
CINCA syndrome aged between 4 and 32 years and with proven 
central nervous system involvement, 5 patients with FCAS aged 
20–64 years and 16 patients with MWS aged 3–75 years of age 
were included ( table 1 ). Patients were excluded if they received 
other immunomodulatory therapies such as methotrexate, had 
been immunised by live vaccinations within the past 3 months 
or if they either showed evidence for a pre-existing underlying 
infection or severe medical conditions such as alcohol abuse, 
recent infections or heart disease. 
 Treatment regimens 
 Anakinra therapy 
 Anakinra (Kineret; Amgen, Cambrige, UK) was applied once 
daily subcutaneously at a dose of 1–2 mg/kg/day. Patients were 
treated with 100 mg/dose in patients ≥40 kg body weight, chil-
dren with persistent disease activity received anakinra in a step-
wise escalated dose to a maximum of 8 mg/kg. If required a 
concomitant non-steroidal anti-infl ammatory drug was given. 
 Canakinumab therapy 
 Canakinumab (Ilaris; Novartis, Basel, Switzerland) was applied 
at a dose of 150 mg subcutaneously for ≥40 kg body weight or 
2 mg/kg for <40 kg body weight every 2 months. If complete 
remission was not achieved by day 8, canakinumab was applied 
intravenously at a dose of 5 mg/kg body weight. 
 IL-1 Trap therapy 
 IL-1 Trap (Rilonacept; Regeneron Pharmaceuticals, Tarrytown, 
New York, USA) was administered weekly subcutaneously. 
The fi rst dose was 300 mg as initial loading dose, followed by 
weekly administration of 100 mg. 
 Clinical and laboratory markers 
 All patients had typical clinical features of CAPS disease. Beside 
the clinical and physicians global assessment, patients recorded 
clinical signs and symptoms in a diary as described previously. 8 
 13  22 Laboratory parameters were determined serially at each visit 
using standardised laboratory testing. This included examination 
of the classical infl ammatory markers ESR, SAA and CRP. CRP 
values <0.5 mg/dl (lower sensitivity level of the used test) were 
defi ned as 0 mg/dl. Laboratory measurements of these infl am-
mation markers were performed at the institutional laboratories 
either in Bethesda or in Tuebingen. Additionally, serum levels of 
MRP8/14 as a marker for phagocyte activation were measured 
for all patients in Muenster. Serum levels of MRP8/14 were deter-
mined by a double-sandwich ELISA system as described previ-
ously. 23 The readers of the laboratory assay were blinded for the 
diagnosis and the infl ammatory activity of the patients. 



















FCAS vs CINCA 
patients
No. male / female 10/8 3/9  5/9  4/1  
Age, median (range) 
(years) at anti-IL-1 therapy
11 (4.1 – 32.0) 21 (3.0–66.5)  29 (4–74.5)  45 (20–64)  
Follow-up on treatment, 
median (range) (months)
18 8 (4–19)  10 (6–15)  28 (24–32)  
MRP8/14 (ng/ml) at 
baseline, mean (range)
2830 (690–8480) 4390 (1790–9780) p=0.07 3000 (500–13060) p=0.56 3600 (300–11 570) p=0.79
ESR (mm/h) at baseline, 
mean (range)
60 (20–138) 32 (6–67) p=0.009 24 (11–49) p<0.001 46 (22–67) p=0.48
CRP (mg/dl) at baseline, 
mean (range)
6.8 (2.7–15.3) 2.1 (0.0–5.0) p<0.001 2.3 (0.0–6.9) P<0.001 5.0 (1.7–8.8) p=0.25
SAA (mg/l) at baseline, 
mean (range)
266 (18–707) 37 (3–91) p=0.02 88 (2–680) p=0.02 190 (39–529) p=0.27
 CINCA, chronic infantile neurological, cutaneous and articular (syndrome); CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FCAS, familial cold autoinfl ammatory 
syndrome; MWS, Muckle–Wells syndrome; SAA, serum amyloid A. 
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 Statistical analysis 
 SPSS version 13.0 (SPSS Inc, Chicago, Illinois, USA) for  windows 
was used for statistical analyses. Differences for parameters 
were compared between groups by Mann–Whitney U test. The 
paired samples were analysed by Wilcoxon test. 
 All tests of signifi cance were two-tailed and a p value of <0.05 
was considered as signifi cant. Upper limit of healthy controls are 
defi ned as mean plus two SDs for MRP8/14, 16 and are defi ned 
for the other infl ammation parameters by the assay manufac-




 By the beginning of the study all patients had active disease, 
as indicated by clinical and laboratory examination. Twelve of 
the patients with CINCA syndrome had mutations in exon 3 of 
 NLRP3 , all other patients were patients with clinically defi ned 
with CINCA. All enrolled patients with FCAS were positive for 
 NLPR3 mutations with a family history of FCAS in all but one 
patient. Twenty-one patients with MWS from four different 
families were screened for inclusion into the study. All patients 
were Caucasians, had clinical diagnosis of MWS and were car-
riers of heterozygous  NLRP3 mutations. A total of 12 patients 
were included in the anakinra cohort. Patients were allowed to 
switch anti-IL-1 therapy for lack of effi cacy or for patient pref-
erence. Ten of these patients later switched to canakinumab 
treatment. Upon discontinuation of anakinra a disease fl are 
had to be awaited. The maximum wait time before the start of 
canakinumab therapy was set at 14 days. A total of 14 patients 
were gathered in the canakinumab cohort. Patients’ and cohort 
 specifi c characteristics are listed in  table 1 . 
 Study duration 
 The mean study duration and the short-term study follow-up 
varied from patient group to patient group (see  table 1 and 
 fi gures 1 – 3 ). This is owing to the different patient cohorts, 
which have been assermbled at different institutions and at 
different time points. Treatment safety was recorded and treat-
ment effi cacy was determined at each follow-up visit with clini-
cal disease activity and infl ammatory markers, including ESR, 
CRP, SAA and MRP8/14. 
 Serum concentrations of infl ammatory markers before 
anti-IL-1 therapy 
 Before the start of treatment all patients with CAPS had raised 
MRP8/14 serum levels compared with healthy controls. 16 
Patients with CINCA syndrome had mean MRP8/14 levels 
of 2830 (range 690–8480) ng/ml, patients with FCAS of 3600 
(300–11 570) ng/ml. Serum samples from patients with MWS 
from the anakinra cohort revealed MRP8/14 concentrations 
of 4390 (1790–9780) ng/ml and in the canakinumab cohort 
the mean serum concentration was 3000 (500–13 060) ng/ml 
 Figure 1  Interleukin (IL-1) blockade in patients with Muckle–Wells syndrome (MWS): anakinra versus canakinumab. (A) Serum concentrations of 
MRP8/14 (myeloid-related proteins); (B) ESR (erythrocyte sedimentation rate); (C) CRP (C-reactive protein) and (D) SAA (serum amyloid A) were 
determined in anakinra- (N=12) and canakinumab-treated patients with MWS (N=14) at baseline, short-term (day 14 in anakinra-treated patients, 
and day 8 in canakinumab-treated patients) and last follow-up (4–19 months in anakinra-treated patients, and 6–15 months in canakinumab-treated 
patients). The scatter plot depicts the measured values for each patient. Horizontal grey line indicates mean. Dashed grey lines indicate the upper limit 
of healthy individuals (MRP < 450 ng/ml, ESR < 20 mm/h, CRP < 0.5 mg/dl, SAA < 10 mg/l). 
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(see  table 1 ,  fi gure 1 ). Mean MRP8/14 serum concentrations of 
the four patient groups did not differ signifi cantly. In contrast, 
classical infl ammatory markers at baseline were signifi cantly 
higher in patients with CINCA syndrome than in patients with 
MWS. This is mainly because ESR, CRP and SAA values of the 
individual patients with CINCA were raised above normal cut-
off values in all cases. In patients with MWS these infl ammatory 
markers were raised only in 64–92% of the cases. Therefore, in a 
substantial number of these patients infl ammatory activity was 
not detectable by ESR, CRP or SAA, but by MRP8/14. 
 Response to anakinra therapy 
 As reported in previous studies all patients with CAPS had an 
immediate clinical response to anakinra. 8 – 10 Dermal symptoms, in 
particular, and overall patient well-being improved as documented 
in the diaries. 8  22 Mean levels of MRP8/14 at day 14 in patients 
with MWS and after 3 months in patients with CINCA (short-
term response) were signifi cantly decreased to 670 ± 640 ng/ml (p 
< 0.001) in patients with CINCA syndrome and to 1315 (300–2510) 
ng/ml (p = 0.003) in patients with MWS. ESR levels decreased in 
both patient groups signifi cantly (CINCA: mean 18 mm/h; p < 
0.001 and MWS: 13 mm/h; p = 0.02). While CRP and SAA levels 
at short-term follow-up in patients with MWS decreased non-sig-
nifi cantly, both classical infl ammation  markers were signifi cantly 
decreased in patients with CINCA (both p < 0.001). 
 Patients with MWS treated with anakinra had raised 
MRP8/14 levels, even in 83% of the cases at the last follow-
up—that is, after 4–19 months, although acute phase reactants 
normalised in the majority of these patients. Individual 
MRP8/14 values varied substantially at that time point so 
mean serum levels increased again, and the difference from 
pretreatment values did not reach signifi cance any more (p = 
0.386). We analysed individual MRP8/14 levels, especially in 
outlier measurements, but we found no obvious correlations 
with more severe disease activity or with clinically defi ned 
fl ares in these patients. One reason for the variance of patient 
values may lie in ongoing subclinical phagocyte activation of 
the patients with MWS, as already detected in patients with 
JIA at risk for fl ares ( fi gure 1 ). 21 
 During follow-up for 18 months of patients with CINCA who 
were receiving anakinra, there was a sustained clinical response to 
treatment in all patients. 8 MRP8/14 serum levels remained lower 
in general, but throughout the study period until last follow-up, at 
least 44% of the patients had levels above the cut-off value of nor-
mal controls ( fi gure 2 ). CRP, ESR and SAA had a similar response 
pattern to that of MRP8/14 and also remained elevated in roughly 
half of the patients with CINCA throughout the whole study 
period. At last follow-up only two patients had normalised levels 
of all four markers of infl ammation (MRP, ESR, CRP and SAA). 
 Response to canakinumab therapy 
 The short-term response rate of patients with MWS to canaki-
numab at day 8 was excellent. Clinical symptoms of the patients 
and global assessment improved. Mean levels of MRP8/14 after 
8 days of canakinumab therapy (short-term end point) were 
 Figure 2  Individual follow-up of patients with chronic infantile neurological, cutaneous and articular (CINCA) syndrome treated with anakinra. 
(A) Serum concentrations of MRP8/14 (myeloid-related proteins); (B) ESR (erythrocyte sedimentation rate); (C) CRP (C-reactive protein) and (D) SAA 
(serum amyloid A) in 18 patients with CINCA before starting of interleukin 1 receptor antagonist (IL-1Ra; anakinra) treatment at baseline, after 3 
months of treatment, after 12 months of treatment and at last follow-up (18 months). The scatter plot depicts the measured values for each patient. 
Horizontal line indicates mean. In general, MRP8/14 serum levels and the other infl ammatory markers mirror the clinical response to treatment 
after starting anakinra therapy. Nevertheless, none of the infl ammation markers normalise (and are less than the cut-off point of healthy controls as 
indicated by the grey dashed line) in a substantial proportion of patients. 
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signifi cantly decreased to 630 (240–1920) ng/ml (p=0.001) 
( fi gure 1 ). In contrast to the anakinra-treated patients levels of 
classical infl ammatory markers had already decreased signifi -
cantly at the short-term end point. None of the canakinumab-
treated patients showed abnormal ESR levels or abnormal CRP 
levels at this time point, only one patient had an abnormal SAA 
value. 
 At last follow-up only 14% of canakinumab-treated patients 
had elevated MRP8/14 levels. Moreover, the mean further 
decreased to 520 (140–3010) ng/ml (p=0.002). ESR, CRP and 
SAA remained in the range of healthy individuals. 
 Response to IL-1 Trap treatment 
 All patients with FCAS responded immediately to the admin-
istration of rilonacept with reduced cold-induced attacks and 
improvement in symptoms. 13 MRP8/14 serum levels in the fi ve 
patients were heterogeneous ( fi gure 3 ). Although the mean lev-
els before treatment were in the same range as for the other 
CAPS diseases and there was a clear downwards trend, the 
small number of patients did not allow signifi cant differentia-
tion between levels before and after successful treatment. ESR, 
CRP and SAA levels during rilonacept treatment reduced sig-
nifi cantly. However, our data suggest that subclinical infl amma-
tory activity may still be present in patients with FCAS receiving 
treatment, which needs to be further analysed in larger sets of 
patients. 
 DISCUSSION 
 Monitoring disease activity in CAPS is challenging. To deter-
mine treatment response, and to possibly adjust treatment, it is 
useful to evaluate infl ammation markers. The main goal of treat-
ment is to prevent organ damage from continuing infl ammation. 
 Figure 3  Individual follow-up of patients with familial cold autoinfl ammatory syndrome (FCAS) treated with interleukin 1 (IL-1) Trap. (A) Serum 
concentrations of MRP8/14 (myeloid-related proteins); (B) ESR (erythrocyte sedimentation rate); (C) CRP (C-reactive protein) and (D) SAA (serum 
amyloid A) in fi ve patients with FCAS before starting IL-1 Trap (rilonacept) treatment at baseline, after 3 months of treatment, after 6 months of 
treatment and at last follow-up (24–32 months). The measured values are heterogeneous in the fi ve patients and have a trend to decrease after the 
start of treatment. Nevertheless, signifi cant differences cannot be seen in this small number of patients. The scatter plot depicts the measured values 
for each patient. Horizontal line indicates mean. Dashed grey line indicates the upper limit of healthy individuals (MRP < 450 ng/ml, ESR <20 mm/h, 
CRP < 0.5 mg/dl, SAA < 10 mg/l). 
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Commonly elevated infl ammatory markers include SAA, CRP 
and ESR. 9 ESR has been used in previous anti-IL-1 studies 
and SAA was previously described as an important predictive 
marker for amyloidosis. 8  9  24 The primary goal of this study was 
to identify the potential of MRP8/14 as a sensitive biomarker for 
IL-1β-driven infl ammation in patients with CAPS. 
 MRP8/14 has been already proposed as an infl ammatory 
marker in rheumatoid arthritis, JIA, infl ammatory bowel dis-
ease and sepsis. 17  25 However, MRP8/14 is most markedly 
elevated in diseases involving systemic autoinfl ammation such 
as systemic-onset JIA. 16 The feedback link between MRP8/14 
and IL-1 hypersecretion, in particular, as described by us previ-
ously, is a key phenomenon in this disease. The close correla-
tion of these molecules, and the diffi culties of measuring IL-1β 
in patient samples are the rationale for analysing MRP8/14 as a 
surrogate marker for IL-1β-driven infl ammation. 15 Our analysis 
of serum samples from patients with CAPS with severe disease 
activity showed signifi cantly elevated MRP8/14 serum levels for 
CINCA, for FCAS and in the same range for patients with MWS. 
These concentrations are in a similar range to those for patients 
with other infl ammatory diseases, in which the MRP8/14 com-
plex has already been proposed as a reliable biomarker for dis-
ease activity. 25 Neither of the measured infl ammation markers 
could be correlated to the clinical phenotype of the different 
CAPS diseases. 
 Response to treatment in the short term was mirrored by 
classical infl ammation markers and by MRP8/14 regardless of 
patient group and treatment. When monitoring disease activ-
ity during IL-1 blockade treatment in the long term, different 
dynamics of infl ammatory markers were found to depend on 
patient and treatment group. Despite clinical response, patients 
with CINCA treated with anakinra displayed slightly elevated 
MRP8/14, CRP, ESR and SAA levels during the whole follow-
up, in accordance with ongoing clinical symptoms such as bony 
overgrowth, this is not responding  to IL-1Ra therapy. Multiple 
determinations of infl ammatory markers may improve the 
diagnostic ability of detecting subclinical disease activity in 
this patient group. Even more striking than in CINCA, anak-
inra-treated patients with MWS in clinical remission had clas-
sical infl ammatory markers in the normal range but MRP8/14 
serum concentrations were still increased, indicating that during 
IL-1Ra therapy some infl ammatory activity may persist or reoc-
cur involving innate immune mechanisms. 
 Clinically useful cut-off values above the normal range are 
hardly to defi ne from these data and should be examined in future 
studies. However, MRP8/14 identifi ed subclinical infl ammation 
in more patients receiving anakinra than when disease activity 
was monitored with acute phase reactants. MRP8/14 was more 
sensitive at day 8 of the canakinumab treatment than classical 
infl ammatory markers. Thus MRP8/14 could be used to identify 
patients who need to adjust their anakinra therapy (increase in 
dose) or those who should be switched to canakinumab. This 
is of clinical relevance, as patients with MWS have a greater risk 
of developing SAA amyloidosis and other disease-related com-
plications. Switching treatment to the anti-IL-1 antibody canaki-
numab led to a signifi cant improvement and normalisation of all 
disease activity parameters including MRP8/14 in the short and 
long term. This refl ects a sustained and stable remission of MWS 
disease activity following canakinumab therapy and indicates 
that MRP8/14 is the most reliable surrogate marker for IL-1β-
driven infl ammation. 
 Conclusions for patients with FCAS may be preliminary, 
because of the small number of patients, and need to be con-
fi rmed in a larger cohort of patients for the analysis of statistical 
signifi cance and also to evaluate how patients with FCAS might 
benefi t from improved medication monitored by biomarkers. 
Interestingly, as for anakinra-treated patients with CAPS, the 
MRP8/14 levels do respond to treatment but remain increased 
above normal values for the whole follow-up. Patients with 
FCAS in this study are generally older, which may represent a 
confounding variable for the comparison of initial MRP8/14 lev-
els, although previously published data showed no differences 
in MRP8/14 values between adults and children. 16 Previous 
studies have suggested the possible dynamics of normalising 
MRP8/14 and of other phagocyte-specifi c S100 protein levels 
during effective anti-infl ammatory treatment in the range of 1–2 
weeks. 15  16  26 
 The phagocyte-specifi c MRP8/14 complex is a marker for 
monocyte and neutrophil activation. Accordingly, MRP8/14 lev-
els might be elevated, while ESR, CRP and SAA, which refl ect 
the acute phase reaction of the liver, remained low or even 
decreased further. A similar phenomenon has been described for 
patients with JIA. Patients with JIA during clinical remission but 
prone to relapse exhibit elevated MRP8/14 serum levels but no 
alterations of the classical infl ammatory markers CRP and ESR. 
Patients with MRP8/14 serum concentrations >700 ng/ml could 
be identifi ed with a sensitivity of about 85% as likely to relapse 
in the next 3 months. 21  27 
 Our data suggest that the MRP8/14 complex is a sensitive 
marker in patients with CAPS, with the ability to detect sub-
clinical, IL-1β-dependent disease activity. Expressed in phago-
cytes, MRP8/14 is released actively into the extracellular space 
upon infl ammatory activation. 28 This cell system is the source 
of a number of proinfl ammatory cytokines and can be found 
at affected sites in several autoimmune diseases. For instance, 
MRP8/14 has been identifi ed in early infi ltrating phagocytes in 
rheumatoid arthritis and vasculitis. 23  29  30 As an endogenous 
danger signal, MRP8/14 mediates early infl ammatory responses 
and recruits immune cells to infl amed tissues. 31 MRP8/14 
induces both increased permeability of endothelial monolay-
ers and raised adhesion of neutrophils to the endothelium. This 
results in increased leucocyte extravasation and further propa-
gates infl ammatory processes. 32  33 Measuring MRP8/14 concen-
trations in the serum of affected individuals is a reliable tool to 
monitor infl ammation at the cellular level. Phagocyte activation 
locally and/or systemically is refl ected, while classical infl amma-
tion markers refl ect late systemic infl ammatory responses. 
 This study illustrates different states of subclinical disease 
activity in patients with CAPS depending on the type of anti-IL-1 
therapy. The study demonstrates (a) increased initial levels of clas-
sical infl ammation markers in patients with CAPS, pronounced 
in CINCA and FCAS and less pronounced in patients with 
MWS, before starting anti-IL-1 therapy; (b) clearly elevated initial 
MRP8/14 serum concentrations in the range of other infl amma-
tory diseases and with no signifi cant difference between CINCA 
and FCAS and MWS; (c) good correlation of classic infl amma-
tion markers and MRP8/14 with early response to treatment 
in patients with CAPS and (d) lower levels of MRP8/14 serum 
concentrations in patients with CAPS successfully treated with 
canakinumab than in anakinra-treated patients, indicating con-
tinuing subclinical disease activity in the latter patients. 
 Taken together, this is the largest biomarker study in CAPS 
to date, investigating all phenotypes of CAPS diseases, treated 
with all types of available anti-IL-1 strategies. The MRP8/14 
complex is a reliable marker for phagocyte activation and is 
therefore an appropriate marker to refl ect the activity of infl am-
mation in CAPS as a surrogate marker for IL-1β. Long-term data 
for anti-IL-1 treatment are still lacking, therefore the impact of 
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probable subclinical disease activity on the later outcome of 
patients will have to be investigated with further longitudinal 
studies. Individualised treatment strategies may evolve in the 
future to identify patients with CAPS with continuing subclini-
cal infl ammation and need for additional/different treatment to 
prevent late sequelae of the disease and to improve the quality 
of life of the patients. 
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